{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:29:51Z","timestamp":1778495391761,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81272890"],"award-info":[{"award-number":["81272890"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ygyno.2016.07.099","type":"journal-article","created":{"date-parts":[[2016,7,17]],"date-time":"2016-07-17T02:53:01Z","timestamp":1468723981000},"page":"68-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV): A report based on our 10-year clinical experiences"],"prefix":"10.1016","volume":"143","author":[{"given":"Junjun","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9112-1021","authenticated-orcid":false,"given":"Yang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xirun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengzhi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.07.099_bb0005","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1200\/JCO.2012.43.1817","article-title":"EMA\/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis","volume":"31","author":"Alifrangis","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.099_bb0010","first-page":"7","article-title":"Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010","volume":"59","author":"Agarwal","year":"2014","journal-title":"J Reprod Med"},{"issue":"5\u20136","key":"10.1016\/j.ygyno.2016.07.099_bb0015","first-page":"199","article-title":"Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score > or = 7","volume":"55","author":"Lurain","year":"2010","journal-title":"J Reprod Med"},{"key":"10.1016\/j.ygyno.2016.07.099_bb0020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/IGC.0000000000000070","article-title":"Analysis of the prognosis and related factors for patients with stage IV gestational trophoblastic neoplasia","volume":"24","author":"Yang","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.07.099_bb0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ygyno.2015.01.530","article-title":"Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome","volume":"137","author":"Savage","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.099_bb0030","first-page":"262","article-title":"Survival of women with gestational trophoblastic neoplasia and liver metastases: is it improving?","volume":"57","author":"Ahamed","year":"2012","journal-title":"J Reprod Med"},{"key":"10.1016\/j.ygyno.2016.07.099_bb0035","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.bjc.6603416","article-title":"The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours","volume":"95","author":"Powles","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.07.099_bb0040","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.1997.15.7.2636","article-title":"EMA\/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients","volume":"15","author":"Bower","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.099_bb0045","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/annonc\/mdq649","article-title":"Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed\/chemoresistant gestational trophoblastic neoplasia","volume":"22","author":"Feng","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.099_bb0050","first-page":"941","article-title":"Efficacy of the FAEV regimen in the treatment of high-risk, drug-resistant gestational trophoblastic tumor","volume":"52","author":"Wan","year":"2007","journal-title":"J Reprod Med"},{"key":"10.1016\/j.ygyno.2016.07.099_bb0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1471-0528.1986.tb07815.x","article-title":"Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984)","volume":"93","author":"Newlands","year":"1986","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.ygyno.2016.07.099_bb0060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1525-1438.2007.00999.x","article-title":"EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients","volume":"18","author":"Lu","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.07.099_bb0065","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ygyno.2003.08.028","article-title":"Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy","volume":"91","author":"Escobar","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.099_bb0070","first-page":"219","article-title":"Management of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine chemotherapy","volume":"56","author":"Cyriac","year":"2011","journal-title":"J Reprod Med"},{"key":"10.1016\/j.ygyno.2016.07.099_bb0075","first-page":"231","article-title":"High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy","volume":"57","author":"Cagayan","year":"2012","journal-title":"J Reprod Med"},{"key":"10.1016\/j.ygyno.2016.07.099_bb0080","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/1097-0142(19900901)66:5<978::AID-CNCR2820660529>3.0.CO;2-3","article-title":"Recurrent gestational trophoblastic disease. Experience of the Southeastern Regional Trophoblastic Disease Center","volume":"66","author":"Mutch","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.07.099_bb0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1471-0528.2009.02420.x","article-title":"Prognosis of patients with relapsed and chemoresistant gestational trophoblastic neoplasia transferred to the Peking Union Medical College Hospital","volume":"117","author":"Feng","year":"2010","journal-title":"BJOG"},{"key":"10.1016\/j.ygyno.2016.07.099_bb0090","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ygyno.2006.04.007","article-title":"Recurrent gestational trophoblastic tumor: management and risk factors for recurrence","volume":"103","author":"Yang","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.099_bb0095","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1525-1438.2006.00606.x","article-title":"Results with EMA\/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia","volume":"16","author":"Turan","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.07.099_bb0100","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1471-0528.1991.tb10369.x","article-title":"Results with the EMA\/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to1989","volume":"98","author":"Newlands","year":"1991","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.ygyno.2016.07.099_bb0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00520-010-1003-x","article-title":"Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity \u2013 state of the art","volume":"19","author":"Grunberg","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ygyno.2016.07.099_bb0110","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.1996.14.10.2769","article-title":"Combination but not singleagent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors","volume":"14","author":"Rustin","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.099_bb0115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0140-6736(91)90490-G","article-title":"Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours","volume":"338","author":"Pedersen-Bjergaard","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2016.07.099_bb0120","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ejca.2012.09.015","article-title":"Comparing cisplatin-based combination chemotherapy with EMA\/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia","volume":"49","author":"Lybol","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.07.099_bb0125","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1200\/JCO.1999.17.2.569","article-title":"Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllo-toxins","volume":"17","author":"Smith","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.099_bb0130","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1200\/JCO.2014.57.5332","article-title":"Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause","volume":"33","author":"Savage","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.099_bb0135","first-page":"204","article-title":"Reproductive outcomes after multiagent chemotherapy for high-risk gestational trophoblastic neoplasia","volume":"59","author":"Wong","year":"2014","journal-title":"J Reprod Med."},{"key":"10.1016\/j.ygyno.2016.07.099_bb0140","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1471-0528.1998.tb10271.x","article-title":"Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome","volume":"105","author":"Woolas","year":"1998","journal-title":"Br. J. Obstet. Gynaecol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816309702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816309702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T09:20:50Z","timestamp":1536571250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816309702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0090825816309702"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.07.099","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV): A report based on our 10-year clinical experiences","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.07.099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}